trovafloxacin   Click here for help

GtoPdb Ligand ID: 13476

Synonyms: CP-99,219 | Trovan® | Turvel®
Approved drug
trovafloxacin is an approved drug (FDA (1997), EMA (1998))
Compound class: Synthetic organic
Comment: Trovafloxacin is a 1,8-naphthyridine derivative, structurally related to the fluoroquinolones. It is a type II DNA topoisomerase inhibitor and has broad-spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria [1-3]. Note that structure shown here matches the PubChem standardized chemical structure. There are varying representations of its stereochemistry across other databases.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 3
Topological polar surface area 99.23
Molecular weight 416.35
XLogP 1.39
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=C(C=C(C(=C1)N2C=C(C(=O)C3=C2N=C(C(=C3)F)N4C[C@H]5[C@@H](C4)C5N)C(=O)O)F)F
Isomeric SMILES C1[C@@H]2[C@@H](C2N)CN1C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F
InChI InChI=1S/C20H15F3N4O3/c21-8-1-2-15(13(22)3-8)27-7-12(20(29)30)17(28)9-4-14(23)19(25-18(9)27)26-5-10-11(6-26)16(10)24/h1-4,7,10-11,16H,5-6,24H2,(H,29,30)/t10-,11+,16?
InChI Key WVPSKSLAZQPAKQ-SOSAQKQKSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Trovafloxacin mesylate was granted approval by the US FDA in 1997 (sold as Trovan® tablets) but has since been discontinued. In 1998, the EMA granted Europe-wide approval for the use of this drug (marketed as Trovan® and Turvel®), but this was withdrawn in 1999 following reports of hepatotoxicity. Trovafloxacin was indicated for use in the treatment of pneumonia, acute exacerbations of chronic bronchitis, acute sinusitis, complicated intra-abdominal infections, acute pelvic and gynaecological infections, and skin and soft tissue infections.